期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 20, 期 -, 页码 45-51出版社
ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12461
关键词
outcome; incidence; Streptococcus pneumoniae; pneumococcal conjugate vaccine; invasive pneumococcal disease; elderly; pneumococcal pneumonia; disease burden; Community-acquired pneumonia
资金
- Pfizer
- Boehringer Ingelheim
- Solvay
- GSK
- Essex Pharma
- MSD
- Novartis
To overview the present global burden of pneumococcal disease is important because new preventive measures such as the pneumococcal conjugate vaccine 13 are currently being evaluated. Pneumococcal disease is roughly divided into non-invasive and invasive disease. The burden of non-invasive pneumococcal disease in adults is mainly determined by community-acquired pneumonia. Pneumococcal pneumonia has high incidence rates and carries a high mortality risk, especially in the elderly. Within the cluster of invasive pneumococcal diseases, pneumonia also represents the most common infectious source. Incidence and mortality rates of both non-invasive and invasive disease have changed as a result of pneumococcal vaccination in children. However, especially elderly patients with comorbidities remain vulnerable to morbidity and mortality caused by pneumococcal disease. The current review summarizes the current knowledge on the epidemiology including outcome of the main clinical forms of pneumococcal disease, with a special focus on elderly patients. Furthermore, the economic burden and future vaccine strategies are briefly discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据